EUVIMEDObjevte EUVIMED
Crossref

Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process Intermediates

Taku Tsukidate iD, Zhenshu Wang, Andrew Hsieh, Patricia Rose, Xuanwen Li iD

Journal of the American Society for Mass Spectrometry · 2025

DOI: 10.1021/jasms.5c00204 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2025. Written by Taku Tsukidate and 4 co-authors. Institution: Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States. Major MEDLINE topics: Antibodies, Monoclonal, Disulfides, Cysteine. Cited 2 times so far (Crossref); 38 references. Funded by: Merck.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Monoclonal antibodies (mAbs) are crucial biotherapeutics in the face of increasing global demand, but their production can be impacted by the reduction of disulfide bonds. This study presents a chemical proteomics workflow aimed at elucidating the mechanisms underlying disulfide bond reduction in mAbs produced from Chinese hamster ovary (CHO) cells. We employed iodoacetamide-desthiobiotin (IA-DTB) and the parallel accumulation and serial fragmentation combined with data-independent acquisition (diaPASEF) methodology for cysteine reactivity profiling and successfully quantified approximately 4,500 cysteine-containing peptides from harvested cell culture fluids (HCCF). Our findings reveal that various protein disulfide oxidoreductases were active in reducing HCCF, offering critical insights into the redox environment affecting mAb stability. Notably, we quantified specific cysteine residues in enzymes such as glutaredoxin and thioredoxin domain-containing protein 12, suggesting potential links between their activity and disulfide bond dynamics. This workflow not only complements conventional abundance proteomics but also enhances our understanding of functional enzyme states in bioprocessing. Ultimately, our approach provides a promising strategy for assessing enzymes contributing to disulfide bond reduction, paving the way for improved manufacturing processes of mAbs.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalDisulfidesCysteineCHO CellsCricetulusAnimalsOxidation-ReductionProteomicsIodoacetamideCricetinaeTandem Mass Spectrometry

Substances

Antibodies, MonoclonalDisulfidesCysteineIodoacetamide

Authors and institutions

  • Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.
  • Biologics Process Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.

ORCID profiles: Taku Tsukidate, Xuanwen Li

Funding

  • Merck

Cite

APA

Tsukidate, T., Wang, Z., Hsieh, A., Rose, P., & Li, X. (2025). Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process Intermediates. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.5c00204

Vancouver

Tsukidate T, Wang Z, Hsieh A, Rose P, Li X. Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process Intermediates. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.5c00204

BibTeX
@article{Tsukidate2025,
  author = {Tsukidate, Taku and Wang, Zhenshu and Hsieh, Andrew and Rose, Patricia and Li, Xuanwen},
  title = {Cysteine Reactivity Profiling Illuminates Monoclonal Antibody Disulfide Bond Reduction Mechanisms in Biopharmaceutical Process Intermediates},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2025},
  doi = {10.1021/jasms.5c00204}
}
Start for free →